Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | RORC | P51449 | 8/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975895 | 0.88 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL4088218 | 0.88 | CYP11B1 (0.47) | CYP11B2CYP11B1CYP3A4RORC | |
| SCHEMBL3977621 | 0.86 | CYP11B1 (0.53) | CYP11B2CYP11B1CYP3A4PSEN1PSEN2 | |
| SCHEMBL3975074 | 0.85 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL8219463 | 0.85 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL3981958 | 0.85 | CYP11B2 (0.57) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL3977142 | 0.83 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP3A4MAPK1 | |
| SCHEMBL3976120 | 0.82 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP3A4MAPK1 | |
| SCHEMBL3980433 | 0.80 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL4094875 | 0.80 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| EP-2057163-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027284-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | CYP17A1, CYP11B1, CYP46A1 | CYP11B2 11/4885CYP11B1 2/4885CYP3A4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.